Loading
Neuroendocrine Tumor Research Advances · Journal article
Biomedicine & Pharmacotherapy · September 5, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study comparing two dosing schedules of [177Lu]Lu-AU-SAR-M1, a novel GRPR-targeting radiotherapeutic antagonist, in mice bearing GRPR-positive prostate cancer xenografts. Both weekly and cyclic dosing regimens slowed tumor growth and improved survival with no observed bone marrow toxicity, but the study is limited to a single murine model and does not establish superiority of either schedule or readiness for human trials.
Controlled preclinical xenograft study with vehicle control. Mice with PC-3 prostate cancer xenografts (GRPR-positive tumors); specific numbers of animals per group not stated.. Intervention: [177Lu]Lu-AU-SAR-M1, 12 MBq per injection, 6 total injections via weekly dosing or cyclic dosing (3 injections/week × 2 weeks, repeated after 4-week interval). Compared with: Vehicle control injections. Not stated.
Median survival in control group was 37 days 50% of tumors were eradicated in both treated groups No significant difference in efficacy between weekly (Group 1) and cyclic 3-injections/week with 4-week interval dosing (Group 2)
Follow-up duration and long-term toxicity beyond bone marrow not detailed No evidence of bone marrow toxicity observed in either treatment regimen
This preclinical work suggests [177Lu]Lu-AU-SAR-M1 warrants further investigation for GRPR-targeted radionuclide therapy in prostate cancer, but the results do not yet inform clinical dosing, patient selection, or safety monitoring. The finding that reduced-frequency dosing did not compromise efficacy is noted but requires confirmation in human trials before changing practice.
Early-phase preclinical study in a murine xenograft model demonstrating proof-of-concept for a novel radiotherapeutic agent with two dosing schedules; results are encouraging but lack human translation, long-term follow-up, and mechanistic detail needed to guide clinical design.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work suggests [177Lu]Lu-AU-SAR-M1 warrants further investigation for GRPR-targeted radionuclide therapy in prostate cancer, but the results do not yet inform clinical dosing, patient selection, or safety monitoring. The finding that reduced-frequency dosing did not compromise efficacy is noted but requires confirmation in human trials before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate and breast cancers and hence serves as a legitimate target for radionuclide therapy (TRT). Radiolabeled GRPR antagonists are attractive radionuclide-carriers for TRT, due to their rapid tissue penetration, fast blood/whole-body clearance and inherent biosafety. We hereby explore the impact of dosing frequency of a GRPR-radioantagonist with improved tumor retention on therapeutic efficacy. For this purpose, we first studied the biodistribution of the recently developed [ 177 Lu]Lu-AU-SAR-M1 in mice to estimate dosimetry. Next, mice with PC-3 xenografts (GRPR-positive) were treated with 6 injections of [ 177 Lu]Lu-AU-SAR-M1 (12 MBq/injection), administered weekly (Group 1) or in 2 cycles of 3 injections/week with a 4-week interval (Group 2); an additional Control group got vehicle injections. Body weight, tumor volume, and blood cell counts were monitored. No evidence of bone marrow toxicity was observed. Both treatment regimens significantly slowed down tumor growth and improved survival. Median survival in the Control group was 37 d, while 50% of tumors were eradicated in the treated groups (no significant difference between groups). These preclinical findings qualify [ 177 Lu]Lu-AU-SAR-M1, as a promising candidate for TRT in patients. Results of this study might be used in the design of follow-up studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.